A 100-Year-Old Patient Received MSC Rega™ Pacemaker Implantation

Kunming, China, 13 May 2021 — A centenarian patient has been successfully implanted with a Rega™ Series pacemaker developed by MicroPort Soaring CRM (Shanghai) Co., Ltd. (“MSC”), a subsidiary of MicroPort Scientific Corporation (00853.HK). The recent procedure was completed in approximately an hour by a team led by Dr. Siming Tao, Director of the Department of Cardiology at the Second People’s Hospital of Yunnan Province, an affiliated hospital of Yunnan University.

According to Dr. Tao, at the time of admission the patient was diagnosed with sick sinus syndrome with a heart rate of only 48 bpm. Dr. Tao and his team recommended a pacemaker implant after a comprehensive consultation with the patient. The team identified the appropriate venous access, leads and pacing site after a thorough preoperative planning and preparation. All physical indicators of the patient remained stable during the operation and his heartbeat returned to normal immediately after implantation. The patient, who was discharged from the hospital three days after the operation, remains in good health to date.

According to Dr. Tao, the Rega™ Series pacemakers, which were launched in March 2018, are ideal for super-elderly patients with thin physique and thin subcutaneous tissues, as the pocket heals faster and more efficiently thanks to the smaller surgical incision required for the implantation.

Currently, pacemaker implantation is the only effective approach for bradycardia treatment to reduce mortality and improve quality of life. When implanted in the human body, this electronic therapeutic device requires an artificial “home”, or what is called a pacemaker pocket. A wide incision heals slower and presents a higher risk of infection, which could affect the patient’s normal life, thus reducing their quality of life. Compared to competing products on the market, the MSC Rega™ Series pacemakers are smaller in size and offer state-of-the-art physiological pacing therapy that better suits those low BMI Chinese patients throughout its 10-12 years’ lifespan.

In China, there are currently about 1 million patients suffering from bradycardia, with about 300,000–400,000 new cases per year. However, only about 100,000 patients receive pacing therapy annually. As the average life expectancy increases, and with the aging of the population and increasing acceptance of pacing therapy, more and more super-elderly patients with arrhythmias will require pacemaker implantation to restore normal heart rates.

As a developer and manufacturer of medical devices in the field of cardiac rhythm management, MSC has always committed itself to the development philosophy of “Created in China” and “Made in China” to provide premium CRM products and services to patients both in China and around the world. In the future, MSC will continue to meet the clinical needs of patients and doctors in China and offer more targeted and refined cardiology treatment and management solutions.